Condition: Melanoma · Cutaneous Squamous Cell Carcinoma · Basal Cell Carcinoma · Sponsor: Melanoma Institute Australia
This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers and other solid tumours. The study will evaluate the documentation, processes, accuracy and utility of the predictive biomarker model in clinical practice.
This description comes directly from the study's public registry record.
Personalised Immunotherapy Program Manager · +61 2 9911 7200 · PIP@melanoma.org.au
Always discuss trial participation with your own doctor first.
| Chris O'Brien Lifehouse | Sydney, New South Wales, Australia | Recruiting |
| Melanoma Institute Australia | Sydney, New South Wales, Australia | Recruiting |
| Westmead Hospital | Sydney, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06536257